- Rockwell Medical (RMTI +12.4%) trades higher in early action.
- Craig-Hallum has initiated the shares at Buy with a $16 price target (slightly less optimistic than the $25 objective Summer Street slapped on the shares post-CRUISE-2).
- The firm thinks SFP is set to become the standard of care.
- Apparently mentioned in the note is RMTI's potential to reduce erythropoiesis stimulating agent usage. This may end up threatening Amgen's (AMGN) Epogen and Aranesp, although, as SA contributor Paulo Santos notes, the potential hit to Aranesp might be a larger concern because Epogen is "losing patent protection now, so it's going to be pressured anyway."